Adrenergic Receptors

Alpha-1 receptors couple to Gq proteins, which activate phospholipase C-beta at the inner membrane. Phospholipase C-beta cleaves a membrane phospholipid into two second messengers: inositol trisphosphate and diacylglycerol. Inositol trisphosphate travels to the endoplasmic reticulum and triggers release of stored calcium into the cytoplasm. This rise in intracellular calcium is the signal that drives smooth muscle contraction throughout the body.

In vascular smooth muscle, the result is vasoconstriction — the dominant effect of norepinephrine and the primary mechanism of drugs like phenylephrine. Alpha-1 receptors are also responsible for mydriasis (contraction of the iris dilator muscle), maintenance of urinary continence (contraction of the internal urethral sphincter), and prostate smooth muscle tone — the pharmacological basis of alpha-1 blockers in treating benign prostatic hyperplasia.

Alpha-2 receptors couple to Gi proteins, which inhibit adenylyl cyclase and reduce intracellular cyclic adenosine monophosphate. The most pharmacologically important location of alpha-2 receptors is on the presynaptic terminals of adrenergic neurons themselves, where they function as autoreceptors.

When norepinephrine accumulates in the synapse, it activates these presynaptic alpha-2 receptors, suppressing further norepinephrine release. This is a negative feedback loop — a braking mechanism that prevents excessive sympathetic outflow. Drugs that activate alpha-2 autoreceptors (clonidine, dexmedetomidine) exploit this mechanism to reduce sympathetic tone centrally, producing antihypertensive and sedative effects. Yohimbine blocks alpha-2 receptors, removes the brake, and increases norepinephrine release.

Alpha-2 receptors are also found postsynaptically in several tissues. In platelets, alpha-2 activation promotes aggregation by inhibiting the cyclic adenosine monophosphate signaling that would otherwise keep platelets quiescent. In pancreatic beta cells, alpha-2 activation suppresses insulin secretion — one mechanism by which epinephrine-mediated stress responses cause hyperglycemia. In the central nervous system, alpha-2 receptors in the locus coeruleus are the primary target of dexmedetomidine, explaining its sedative and anxiolytic effects without respiratory depression.

D1 receptors couple to Gs proteins, raising cyclic adenosine monophosphate similarly to beta receptors. They are expressed in the renal afferent arteriole and mesenteric vasculature, where their activation causes vasodilation. In the kidney, this vasodilation increases renal blood flow. D1 receptors in the proximal tubule also reduce sodium reabsorption, producing a natriuretic effect. These two actions — renal vasodilation and natriuresis — formed the rationale for the now-abandoned practice of low-dose dopamine infusion in patients at risk for acute kidney injury.

Multiple randomized controlled trials, including a landmark trial by the Australian and New Zealand Intensive Care Society, demonstrated definitively that low-dose dopamine does not protect the kidneys from injury and should not be used for renal protection. This is a well-established negative finding in critical care medicine.

D2 receptors couple to Gi proteins and inhibit adenylyl cyclase, analogous to alpha-2 receptors. In the periphery, D2 receptors on sympathetic nerve terminals inhibit norepinephrine release. D2 receptors in the gut inhibit gastrointestinal motility — the target of metoclopramide's prokinetic effect, which works partly by blocking these peripheral D2 receptors. In the chemoreceptor trigger zone of the area postrema — a region at the brainstem surface that lacks a functional blood-brain barrier — D2 receptor activation stimulates nausea and vomiting. This explains why dopamine infusions and dopamine agonist drugs commonly cause nausea, and why D2 antagonists such as metoclopramide and prochlorperazine are effective antiemetics.

Regular use of short-acting beta-2 agonists such as albuterol exposes bronchial smooth muscle receptors to sustained agonist stimulation. Over days to weeks, this drives receptor internalization and reduced gene expression, decreasing the density of beta-2 receptors on the cell surface. The clinical result is tachyphylaxis — shorter duration of bronchodilation, reduced peak effect, and progressively less relief from the same inhaler dose. Patients who use rescue inhalers more than twice a week are exhibiting a pattern that leads to this downregulation, which is one reason why inhaled corticosteroids — not increasing the dose of short-acting agonists — are the appropriate escalation in persistent asthma.

The reciprocal process occurs with chronic beta-blocker therapy. When beta-1 receptors are chronically blocked, the adrenergic system compensates by upregulating receptor density — increasing the number of receptors on cardiac myocytes. If the beta-blocker is then stopped abruptly, normal circulating catecholamine levels suddenly encounter a supersensitive, upregulated receptor population. The result is rebound tachycardia, hypertension, angina, and in patients with coronary artery disease, a real risk of myocardial infarction.

This is the pharmacological basis for the clinical rule that beta-blockers must always be tapered gradually over one to two weeks before discontinuation — never stopped abruptly, especially in patients with known coronary artery disease or those in the perioperative period.

Chronic heart failure is characterized by persistent sympathetic activation and chronically elevated norepinephrine levels in the cardiac interstitium. This sustained catecholamine exposure drives progressive downregulation of cardiac beta-1 receptors, which can fall to 50 percent or less of normal density in advanced heart failure. The result is impaired contractile reserve — the heart cannot mount an adequate adrenergic response to increased demand.

Paradoxically, the treatment for this receptor depletion is not more sympathetic stimulation but less: carvedilol and metoprolol succinate, by blocking the chronically elevated adrenergic drive, allow gradual recovery of beta-1 receptor density over months of therapy. This receptor resensitization is one mechanism contributing to the well-established mortality benefit of beta-blockers in heart failure with reduced ejection fraction.